Fmr LLC lowered its position in Repros Therapeutics Inc. (NASDAQ:RPRX) by 3.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 1,540,844 shares of the biotechnology company’s stock after selling 47,200 shares during the period. Fmr LLC owned 5.76% of Repros Therapeutics worth $709,000 as of its most recent filing with the SEC.

Separately, Allegis Investment Advisors LLC lifted its position in shares of Repros Therapeutics by 8.9% during the 2nd quarter. Allegis Investment Advisors LLC now owns 398,792 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 32,602 shares during the period. Hedge funds and other institutional investors own 13.75% of the company’s stock.

Separately, Laidlaw downgraded shares of Repros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, July 21st.

Repros Therapeutics Inc. (NASDAQ:RPRX) opened at $0.41 on Friday. Repros Therapeutics Inc. has a 1 year low of $0.26 and a 1 year high of $2.15.

Repros Therapeutics (NASDAQ:RPRX) last released its earnings results on Monday, August 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.14. Repros Therapeutics had a negative net margin of 56,062.07% and a negative return on equity of 412.64%. The company had revenue of $0.01 million for the quarter.

COPYRIGHT VIOLATION WARNING: “Repros Therapeutics Inc. (RPRX) Stake Lessened by Fmr LLC” was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/repros-therapeutics-inc-rprx-stake-lessened-by-fmr-llc/1695040.html.

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repros Therapeutics Inc. (NASDAQ:RPRX).

Institutional Ownership by Quarter for Repros Therapeutics (NASDAQ:RPRX)

Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.